Filing Flows

Filing Flows › Strata Critical Medical (SRTA) › How it makes money

How Strata Critical Medical (SRTA) makes money

Strata Critical Medical (SRTA) made $74.1M of revenue in the third quarter 2026 (Q3 2026), +50% from a year earlier. Logistics brought in $44.9M (61%); Clinical brought in $29.2M (39%).

Drawing the Sankey…

Strata Critical Medical revenue by segment, Q3 2026Strata Critical Medical revenue by segment, Q3 2026Logistics$44.9MClinical$29.2M
Strata Critical Medical: revenue by line, Q1 2026 to Q3 2026Strata Critical Medical: revenue by line, Q1 2026 to Q3 2026LogisticsClinicalLogistics: $44.9M latest$44.9MClinical: $29.2M latest$29.2MQ1 2026Q2 2026Q3 2026
Logistics went from 71% of revenue in Q1 2026 to 61% in Q3 2026, the largest shift in the mix.
Strata Critical Medical revenue by quarterStrata Critical Medical revenue by quarter$54.3MQ1 2025$70.8MQ2 2025$49.3MQ3 2025$66.8MQ4 2025$67.4MQ1 2026$72.5MQ2 2026$74.1MQ3 2026
Strata Critical Medical: where each dollar of revenue goesStrata Critical Medical: where each dollar of revenue goesOperating cash flow13¢Free cash flow12¢

Revenue by segment, Q3 2026

SegmentRevenueShareQ/QY/Y
Logistics$44.9M60.6%-7%-3%
Clinical$29.2M39.4%+20%+946%

Where each dollar of revenue goes

LineQ3 2026% of revenue
Revenue$74.1M100.0%
Operating cash flow$9.5M12.8%
Free cash flow$8.6M11.7%

Revenue, quarter by quarter

QuarterRevenueY/Y
Q3 2026$74.1M+50%
Q2 2026$72.5M+61%
Q1 2026$67.4M+87%
Q4 2025$66.8M+84%
Q3 2025$49.3M+37%
Q2 2025$70.8M+4%
Q1 2025$54.3M+5%

From Strata Critical Medical's 10-Q filed Nov 3, 2026 (on EDGAR).

Questions

How does Strata Critical Medical make money?

Strata Critical Medical (SRTA) made $74.1M of revenue in the third quarter 2026 (Q3 2026), +50% from a year earlier. Logistics brought in $44.9M (61%); Clinical brought in $29.2M (39%).

What is Strata Critical Medical's biggest business?

Logistics: $44.9M in the third quarter 2026, 61% of revenue, -3% from a year earlier.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.